226 articles
Entospletinib
Entospletinib (GS-9973) is an oral, selective SYK inhibitor for hematologic malignancies; 61% ORR in relapsed/refractory CLL, 32.7% after BCR inhibitors; not FDA approved.
Envonalkib citrate (TQ-B3139)
Envonalkib citrate (TQ-B3139, CT-711; brand Anluoqing, 安洛晴) is an oral ALK/ROS1/c-Met inhibitor approved in China in June 2024 for first-line ALK-positive advanced NSCLC, with phase III PFS of 24.87 months versus 11.60 for crizotinib.
Enzastaurin
Enzastaurin (LY317615, AR101) is an oral PKCβ-selective kinase inhibitor developed by Eli Lilly for solid and hematologic cancers; it failed phase III testing in DLBCL and glioblastoma and was never approved.
ERAS-0015
JYP0015 (ERAS-0015, JYP-0015) is an oral pan-RAS molecular glue from Guangzhou JOYO Pharma, licensed to Erasca, in Phase 1/2 trials for RAS-mutant pancreatic, lung, and colorectal cancers.
ERAS-4001
ERAS-4001 is Erasca's oral pan-KRAS inhibitor, in-licensed from Medshine Discovery, that binds mutant and wild-type KRAS while sparing HRAS/NRAS; it is in the BOREALIS-1 Phase 1 trial (NCT07021898) for KRAS-mutant solid tumors, with monotherapy data expected in H2 2026.
Eratrectinib
Anrotinib (Willcell TRK inhibitor) denotes eratrectinib (安瑞曲替尼, VC004, brand Weimaituo), Jiangsu Vcare's next-generation pan-TRKA/B/C inhibitor for NTRK fusion solid tumors, conditionally approved in China June 2026 at 50 mg twice daily.
Erdafitinib
Erdafitinib (Balversa) is an oral pan-FGFR kinase inhibitor for metastatic urothelial carcinoma with susceptible FGFR3 alterations after prior therapy including a PD-1/PD-L1 inhibitor; THOR showed survival benefit over chemotherapy.
Everolimus plus lenvatinib
Everolimus plus lenvatinib is a targeted-therapy combination pairing an mTOR inhibitor with a multikinase inhibitor, approved by the FDA in 2016 for advanced renal cell carcinoma.
Famitinib
Famitinib (SHR1020, Abit), a HengRui sunitinib-analogue multi-targeted TKI inhibiting c-Kit, VEGFR-2/3, PDGFR, FLT3, Ret; approved in China May 2025 with camrelizumab for cervical cancer.
Fanregratinib
Fanregratinib (HMPL-453, ATLED, 凡瑞格拉替尼) is HUTCHMED's oral selective FGFR1/2/3 inhibitor for FGFR2-fusion intrahepatic cholangiocarcinoma; its pivotal Phase II showed 42.5% ORR and 16.6-month median OS, with NMPA priority review in December 2025.
FCN-338 (LOXO-338)
FCN-338 (LOXO-338, LY3847429) is an oral selective BCL-2 inhibitor developed by Fochon Pharmaceuticals (Fosun Pharma), licensed to Eli Lilly in 2020, discontinued by Lilly in 2022, and still in Phase I/II trials in China.
Fedratinib
Fedratinib, sold as Inrebic, is an oral kinase inhibitor targeting JAK2, approved by the FDA in August 2019 for adults with intermediate-2 or high-risk myelofibrosis.
Firmonertinib
Firmonertinib (formerly furmonertinib, alflutinib, AST2818; brand Ivesa) is an oral third-generation EGFR TKI approved in China since 2021 for EGFR-mutated NSCLC, with strong CNS activity, and in global development by ArriVent for uncommon EGFR mutations.
Flumatinib
Flumatinib (HH-GV-678, Hansoh Xinfu, 豪森昕福) is a second-generation BCR-ABL tyrosine kinase inhibitor approved in China (2019) for newly diagnosed chronic-phase CML; FESTnd showed superior molecular responses to imatinib.
Fluzoparib
Fluzoparib, renamed fuzuloparib (AiRuiYi, SHR-3162), is an oral PARP1/2 inhibitor by Jiangsu Hengrui, approved in China in 2020 for BRCA-mutated recurrent ovarian cancer and studied in breast cancer.
Forodesine
Forodesine (BCX-1777, Immucillin H, Mundesine) is a transition-state analogue inhibitor of purine nucleoside phosphorylase for T-cell malignancies; approved in Japan 2017 for relapsed/refractory peripheral T-cell lymphoma, not elsewhere.
Fosbretabulin
Fosbretabulin (CA4P, ZYBRESTAT, combretastatin A4 phosphate) is an investigational vascular disrupting agent, a tubulin-binding prodrug from Combretum caffrum that collapses tumor blood vessels; trialed in thyroid, lung, and ovarian cancer without proven survival benefit.
Fovinaciclib citrate capsules
Fovinaciclib citrate capsules (枸橼酸伏维西利胶囊, Futuoning) are a Chinese class 1 oral CDK4/6 inhibitor by Jinzhou Ahon/Fosun, NMPA-approved May 2025 with fulvestrant or aromatase inhibitors for HR+/HER2- advanced breast cancer.
Fulzerasib (GFH925, IBI351)
Fulzerasib (GFH925, IBI351; Dupert, 达伯特) is an oral covalent KRAS G12C inhibitor from GenFleet/Innovent, approved by China's NMPA in August 2024 for previously treated advanced KRAS G12C-mutant NSCLC, with phase 2 ORR 49.1% and mPFS 9.7 months.
Ganetespib
Ganetespib (STA-9090), a second-generation resorcinol HSP90 inhibitor developed by Synta Pharmaceuticals for cancer; its phase III GALAXY-2 lung cancer trial was stopped for futility and development is inactive.
Garsorasib (D-1553)
Garsorasib (D-1553, brand AnFangning, 格索雷塞) is InventisBio's oral covalent KRAS G12C inhibitor, approved in China in November 2024 for previously treated KRAS G12C-mutated advanced NSCLC; phase 2 ORR 52.0%, licensed to Chia Tai Tianqing.
GFH009 (CDK9 inhibitor; SLS009)
GFH009, also called SLS009 or tambiciclib, is a highly selective small-molecule CDK9 inhibitor in-licensed by SELLAS from GenFleet, developed for relapsed/refractory AML and lymphomas, with FDA orphan drug and fast-track designations and Phase 2a venetoclax-azacitidine combination testing.
Gilteritinib
Gilteritinib (brand name Xospata) is an oral FLT3 inhibitor approved in the United States in 2018 for relapsed or refractory acute myeloid leukemia with an FLT3 mutation.
Glecirasib citrate tablets
Glecirasib citrate tablets (枸橼酸戈来雷塞片, Ailikai) are an oral KRAS G12C inhibitor (JAB-21822) by Jacobio/Allist, approved in China May 2025 for previously treated KRAS G12C-mutated advanced NSCLC; phase II ORR 47.9%, mPFS 8.2 months.
Glumetinib
Glumetinib (谷美替尼, gumarontinib, SCC244, brand Haiyitan) is a selective type Ib MET tyrosine kinase inhibitor approved in China (2023) and Japan (2024) for MET exon 14 skipping-mutant advanced NSCLC, dosed 300 mg once daily, with GLORY phase II ORR 66%.
Golidocitinib (DZD4205)
Golidocitinib (DZD4205) is an oral, highly selective JAK1 inhibitor developed by Dizal Pharmaceuticals, approved in China in 2024 for relapsed or refractory peripheral T-cell lymphoma.
H3B-6545
H3B-6545 is Eisai's oral selective estrogen receptor covalent antagonist (SERCA) that covalently binds C530 of ERalpha, inhibiting wild-type and mutant receptor in ER+/HER2- breast cancer; phase 1/2 testing showed 450 mg QD with ORR 20.2% and higher activity in ESR1 Y537S-mutant disease.
HH2853 (EZH1/2 inhibitor)
HH2853 (HH 2853, HH-2853) is an oral dual EZH1/EZH2 inhibitor from Haihe Biopharma that blocks H3K27 methylation; phase I/II trials show responses in PTCL and epithelioid sarcoma.
HRS-1167 (PARP1 inhibitor)
HRS-1167 (M9466) is Jiangsu Hengrui's oral, second-generation selective PARP1 inhibitor with DNA trapping activity, licensed to Merck KGaA in 2023 for EUR160 million and later discontinued by Merck; distinct from Merck & Co's MK-1167 Alzheimer's drug.
Ibrutinib plus obinutuzumab
Ibrutinib plus obinutuzumab is a chemotherapy-free combination regimen pairing the oral BTK inhibitor ibrutinib with the anti-CD20 antibody obinutuzumab, FDA approved in 2019 for previously untreated chronic lymphocytic leukemia.